Minireviews
Copyright ©The Author(s) 2021.
World J Gastrointest Oncol. Jun 15, 2021; 13(6): 560-573
Published online Jun 15, 2021. doi: 10.4251/wjgo.v13.i6.560
Table 1 Absolute and expanded indications for endoscopic submucosal dissection in early gastric cancer patients in Japanese Gastric Cancer Association guideline version 4, 2014 and version 5, 2018
T1a
T1b
UL (-)
UL (+)
SM1 (< 500 µm)
SM2 (> 500 µm)
≤ 2 cm
> 2 cm
≤ 3 cm
> 3 cm
≤ 3 cm
> 3 cm
≤ 3 cm
> 3 cm
JGCA guideline (version 4, 2014)
DifferentiatedESDEXPANDED(JCOG0607)EXPANDED(JCOG0607)SURGERYEXPANDEDSURGERYSURGERYSURGERY
UndifferentiatedEXPANDEDSURGERYSURGERYSURGERYSURGERYSURGERYSURGERYSURGERY
JGCA guideline (version 5, 2018)
DifferentiatedESDESDESDSURGERYEXPANDEDSURGERYSURGERYSURGERY
UndifferentiatedEXPANDED(JCOG1009/1010)SURGERYSURGERYSURGERYSURGERYSURGERYSURGERYSURGERY
JGCA: Japanese Gastric Cancer Association; T1a: Mucosal carcinoma; T1b: Submucosal carcinoma; ESD: Endoscopic submucosal dissection absolute indication; EXPANDED: Endoscopic submucosal dissection expanded indication; SURGERY: Surgical indication; EGC: Early gastric cancer; UL (-): Without ulcer; UL (+): With ulcer; SM1: The submucosal invasion depth is less than 500 µm; SM2: The submucosal invasion depth is more than 500 µm.